A Phase 2 trial of INT-767 in nonalcoholic steatohepatitis (NASH) patients with fibrosis
Latest Information Update: 10 May 2017
At a glance
- Drugs INT 767 (Primary)
- Indications Fibrosis; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- 04 May 2017 According to an Intercept Pharmaceuticals media release, company plans to initiate this trial in second half of 2017.
- 01 Mar 2017 New trial record
- 23 Feb 2017 According to an Intercept Pharmaceuticals media release, company has planned initiation of this trial in 2017.